Tag: Keytruda
Enfortumab Vedotin + Pembrolizumab Significantly Extends OS and PFS in...
Results from the Phase 3 EV-302/KEYNOTE-A39 clinical trial for enfortumab vedotin (Padcev®; Astellas/Seagen) in combination with pembrolizumab (Keytruda®; Merck & Co/MSD) versus chemotherapy, presented at the European Society for Medical Oncology (ESMO) Congress 2023
Combinations with Datopotamab Deruxtecan Show Promising Clinical activity in Treatment of...
Initial results from the TROPION-Lung02 Phase Ib trial demonstrated that that datopotamab deruxtecan (Dato-DXd), a specifically designed TROP2-directed DXd antibody drug conjugate (ADC) being...
Combination of Enfortumab Vedotin with Pembrolizumab Shows Positive Topline Results as...
Cisplatin-based combination chemotherapy has been widely accepted as the first-line treatment option for cisplatin-eligible patients diagnosed with locally advanced or metastatic urothelial cancer (mUC)...
Merck & Co and Seattle Genetics Sign Exclusive Licensing and Co-Development...
Merck & Co and Seattle Genetics have signed an exclusive licensing and co-developing agreement to globally develop and commercialize ladiratuzumab vedotin an investigational antibody-drug...
Potential Accelerated Approval for Enfortumab Vedotin in Combination with Pembrolizumab as...
Updated data from the phase Ib/II multicohort EV-103 trial (NCT03288545; also known as KEYNOTE-869) of enfortumab vedotin* (Padcev™; Seattle Genetics/Astellas Pharma) in combination with...
Updated Results from Trial Shows Enfortumab Vedotin + Pembrolizumab to Shrink...
Updated findings from EV-103, a phase Ib/II clinical trials of enfortumab vedotin* (Padcev™; Astellas Pharma/Seattle Genetics) in combination with pembrolizumab (Keytruda®; Merck Sharp &...
Novel Treatments are a Positive Development for Patients with Metastatic Urothelial...
This week has brought welcome news to bladder cancer patients and their loved ones. Two drugs with great potential for combatting different types of...
Avacta and OncoSec Develop Innovative Gene Delivery of Therapeutic Affimers
Avacta Group, the developer of Affimer® biotherapeutics and reagents, and OncoSec Medical, a company developing intratumoral cancer immunotherapies, have entered into a research collaboration...
Combination of SGN-LIV1A + Pembrolizumab to be Investigated as First Line...
Breast cancer is a cancer which forms in breast tissue. Metastatic breast cancer occurs when the cancer has spread to other parts of the...
Brentuximab Vedotin Identified as Potentially Transformational in Hodgkin’s lymphoma Treament
Earlier this month, during the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), held in Orlando, Florida from December 5–8,...
